AIM ImmunoTech Inc. (AIM) Stock Price & Analysis
AIM ImmunoTech Inc. (AIM) — MoonshotScore 18/100 (Weak band), calculated Oct 5, 2026. Price $0.18 (-4.10%), as of the Oct 2, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
AIM ImmunoTech Inc. · AIM
AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders. Their lead products include Ampligen for chronic fatigue syndrome and Alferon N Injection for genital warts.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · AIM ImmunoTech (AIM)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and an expensive valuation, though growth is only middling, and the price trend has turned against it. Business Quality: Poor; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Flat; Momentum: Falling.
- quarterly revenue $26,000 (Q2 FY2026, quarter ended Jun 30, 2026)
- EPS beat 3 of 8
- ROE 261.8% · current ratio 1.01
Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 18 | Weak | |
| 18 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 18 | Weak | |
| 18 | Weak |
The score was 18 in the stored Oct 4, 2026 snapshot and remains 18 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +5; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.18 | |
| Change on the day | -4.10% | |
| 52-week range | $0.18 – $2.79 | |
| Price / earnings (trailing) | -0.37 | |
| Shares traded on the day | 1.21M |
Price & events
Other perspectives
Council score for AIM ImmunoTech (AIM): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 8, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the AIM film — every key number, told as a short cinematic story
~2 min · open the film
What is AIM ImmunoTech (AIM), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. AIM ImmunoTech Inc. (AIM) is the company analyzed here. It employs 19 people and is led by Thomas K. Equels. In Q2 FY2026 it reported revenue of $26,000 and net income of -$4M.
What do the latest results show for AIM ImmunoTech (AIM)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $26,000. Against analyst estimates the company has EPS beat 3 of 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $26,000 | -$4M | -$0.22 (diluted) |
| Q1 FY2026 | $22,000 | -$3M | -$0.69 (diluted) |
| Q4 FY2025 | $21,000 | -$4M | -$1.36 (diluted) |
| Q3 FY2025 | $26,000 | -$3M | -$1.57 (diluted) |
What are the financial strengths and risks for AIM ImmunoTech (AIM)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Piotroski F 3. Trailing ratios: ROE 261.8% · current ratio 1.01.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How is AIM ImmunoTech scored?
Short answer · as of
A same-model peer rank is unavailable in the current peer set. The MoonshotScore combines business quality, financial safety, valuation, growth durability and momentum; open “Why this rating?” for the method and drivers.
| Company | Price | Market value | Score |
|---|---|---|---|
| $37.32 Date unavailable | $166B | — Model unavailable | |
| $504.73 Date unavailable | $128B | — Model unavailable | |
| $735.20 Date unavailable | $75.7B | — Model unavailable | |
| $919.21 Date unavailable | $57.2B | — Model unavailable | |
| $219.72 Date unavailable | $29.4B | — Model unavailable | |
| $57.16 Date unavailable | $25.3B | — Model unavailable | |
| $115.30 Date unavailable | $23.4B | — Model unavailable | |
| $541.70 Date unavailable | $23.0B | — Model unavailable | |
| $58.39 Date unavailable | $14.7B | — Model unavailable | |
| $143.18 Date unavailable | $14.4B | — Model unavailable | |
| $227.87 Date unavailable | $14.2B | — Model unavailable | |
| $109.86 Date unavailable | $13.0B | — Model unavailable |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 3
- Purchases
- 3
- Sales
- 0
- Other transactions
- 9
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about AIM ImmunoTech (AIM)?
What Investors Ask About AIM ImmunoTech (AIM)
These answers are editorial: 1 of these 9 answers is drawn from the AIM research dossier (written Jun 1, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for AIM?
AIM carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for cancers, viral diseases, and immune-deficiency disorders.
Is AIM a good stock to buy?
Stock Expert AI does not rate AIM buy, sell or hold. AIM ImmunoTech Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the AIM stock price today?
The last price recorded on this page for AIM ImmunoTech Inc. (AIM) is $0.18, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about AIM stock?
Analyst coverage of AIM ImmunoTech Inc. is limited, reflecting its micro-cap status and speculative nature. Key valuation metrics are difficult to assess due to the company's negative profit and gross margins.
What are the key factors to evaluate for AIM?
AIM ImmunoTech Inc. (AIM) holds a MoonshotScore in the low range. The global genital warts treatment market is expected to grow, driven by increasing awareness and diagnosis rates. Not financial advice.
How frequently does AIM data refresh on this page?
AIM's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven AIM's recent stock price performance?
AIM ImmunoTech Inc. (AIM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary drug formulations (Ampligen and Alferon N Injection). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AIM overvalued or undervalued right now?
AIM ImmunoTech Inc. (AIM) is loss-making, so its trailing P/E is negative (-0.37x) and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research AIM before investing?
Before investing in AIM ImmunoTech Inc. (AIM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (17 figures)
The 17 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 9 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $0.18 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T19:24:35.517Z. | |
px.change | Change on the day | -4.10% | FMP | Financial Modeling Prep (FMP) · quote | |
px.change_abs | Change on the day, in dollars | −$0.0077 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $26,000 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.pe | Price / earnings (trailing) | -0.37 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.21M | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_income | Net income, Q2 FY2026 | -$4M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
own.insiders | Insider transactions via FMP | 12 transactions · 3 purchases, 0 sales, 9 other transactions · 3 identified insiders · most recent available transactions | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 6 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-07 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 261.8% · current ratio 1.01 | — | UNRECORDED | Stored key metrics — Date unknown |
px.range52 | 52-week range | $0.18 – $2.79 | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 | |
id.employees | Employees | 19 | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 | |
id.ceo | Chief executive | Thomas K. Equels | UNRECORDED | Stored company-profile observation — Captured 2026-09-29 | |
fin.scores | Distress and quality screens | Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 18 of 100 · Weak · pillars 11 / 11 / 13 / 40 / 14 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 18 (stored snapshot Oct 4, 2026) → 18 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive. |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.